Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/d5/60/7a/d5607a7e-117a-0344-e05f-653d19125116/mza_2005314729548216763.jpg/600x600bb.jpg

Medsider: Learn from Medtech and Healthtech Founders and CEOs

Scott Nelson

225 episodes

2 weeks ago

Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.

All content for Medsider: Learn from Medtech and Healthtech Founders and CEOs is the property of Scott Nelson and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Entrepreneurship

Business,

Management

https://img.transistor.fm/Kms-8BKGFizMW-ZAv1uca9zNKEMhWiyuxnyju8NcINA/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hOWE5/MWVjYTAxMjI5YWY0/MGY3OGVhZWM5M2Nl/MTk0Yy5qcGc.jpg

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD

Medsider: Learn from Medtech and Healthtech Founders and CEOs

52 minutes

4 weeks ago

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD

In this episode of Medsider Radio, we sat down with Andrew Holman, MD, CEO of Inmedix.

Inmedix is commercializing CloudHRV, an FDA-cleared diagnostic that quantifies biological stress with clinical precision to guide treatment decisions in autoimmune disease and beyond.

Andrew is a practicing rheumatologist in Seattle with 25 years of clinical and research experience. His discoveries linking autonomic dysfunction to autoimmune disease outcomes led to a $10 million patent sale to Boehringer Ingelheim. After a decade in retirement, he returned to found Inmedix and pioneer the field of immuno-autonomics — preparing the market for his technology years before launch.

In this interview, Andrew shares how to build a category before commercializing a product, why clinical evidence creates competitive moats that money can't replicate, and how to raise capital from angel investors by understanding what they actually care about.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Andrew Holman.